Optune Pax
Novocure, GmbH · Decision date Feb 11, 2026
What did the FDA approve?
FDA approved PMA P250034 for Optune Pax on February 11, 2026. The applicant is Novocure, GmbH, and the device is categorized as a low electric field generator for pancreatic cancer treatment under product code SHC.
The approval statement describes intended use in adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. The record does not include supplement type or supplement reason, so no change to a prior approval is documented here. The specialty field lists General, Plastic Surgery.
FDA approval order statement
Optune Pax is intended for treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Feb 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250034
- Regulatory pathway
- Premarket approval application
- Applicant
- Novocure, GmbH
- Product code
- SHC
- Decision code
- APPR
- Decision date
- Feb 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Low Electric Field Generator for Pancreatic Cancer Treatment.
- Applicant
- Novocure, GmbH
- Product code
- SHC
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250034 received
Application receipt date recorded by FDA.
P250034 · FDA decision
APPR
P250034/S004 · Related supplement
Optune Pax
Timeline entries are records held by MedtechLedger for P250034. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250034
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune PaxP250034/S004 | Novocure, GmbH | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P250034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records